A new monoclonal antibody against ErbB2, known as 2C4, inhibits the growth of breast tumors that express low and high levels of ErbB2 and the growth of prostate tumors that are resistant to hormone blocking drugs, animal study findings indicate.
Trastuzumab (Herceptin), an anti-ErbB2 antibody, has been shown to be an effective treatment for breast cancer. However, the drug only works against tumors that express high levels of ErbB2. Similarly, while trastuzumab has been shown to inhibit the growth of testosterone-dependent prostate tumors, it has little effect on testosterone-independent tumors.
In the current study, Dr. David B. Agus, from Cedars-Sinai Medical Center in Los Angeles, and colleagues tested the efficacy of 2C4 against cancer cell lines in culture and against breast and prostate human tumors grown in mice. The findings are published in the August issue of Cancer Cell.
e-Med Tools
קצר קולע וממוקד
e-Med סמינרים
אי-מד תחקירים
Medscape Tools
Journal Club
מרכזי מידע ושירות
Facebook
מידע למפרסם
מאגר תרופות
מאגר אנשי המקצוע
אינדקס שימושי
חדשות משה"ב
eMed HealthClub
מחקרים קליניים
השאירו תגובה
רוצה להצטרף לדיון?תרגישו חופשי לתרום!